Verition Fund Management
SABS icon

Verition Fund Management’s SAB Biotherapeutics SABS Stock Holding History

Verition Fund Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,867
Closed -$100K – 3361
2025
Q4 		$100K Buy
+26,867
New +$88.4K ﹤0.01% 3306

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Verition Fund Management's SABS Position: Q1 2026 in Review

Verition Fund Management sold out of SAB Biotherapeutics (SABS) in Q1 2026, closing a stake of 26,867 shares — an estimated $100K sold.

Verition Fund Management first reported a position in SABS in Q4 2025 and held it in 1 quarter. The position peaked at $100K in Q4 2025. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Verition Fund Management reported no remaining SAB Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 26,867 SAB Biotherapeutics shares in Q1 2026, an estimated $100K.
  • Verition Fund Management first reported a position in SAB Biotherapeutics in Q4 2025 and held it in 1 quarter.
  • Verition Fund Management's SAB Biotherapeutics position peaked at $100K in Q4 2025.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.